News & Updates

A meta-analysis presented at ADA 2026 supports the benefits of hyperbaric oxygen therapy (HBOT) for ulcer healing and reducing the risk of major amputation in individuals with diabetic foot ulcers (DFUs).

ARACOG, a phase II randomized trial, reports a significantly greater decline in objectively assessed cognitive function for advanced prostate cancer patients treated with enzalutamide vs darolutamide over 24 weeks, according to data presented at ASCO 2026.

Chiauranib plus weekly paclitaxel significantly extends progression-free survival (PFS) in patients with platinum-resistant or -refractory ovarian cancer, including those previously treated with anti-angiogenic agents, according to the findings of the phase III CHIPRO trial presented at ASCO 2026.